Overview

Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Suzhou Junde Biotechnology Co., Ltd
Treatments:
Paclitaxel